Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4
Notice: Undefined index: HTTP_ACCEPT_LANGUAGE in /home/stockstowatch/public_html/wp-content/mu-plugins/GrULw0.php on line 4 SmartPros (SPRO) – Spero Therapeutics Shares Jump After Upbeat FDA Feedback For Tebipenem HBr Program – Stocks to Watch
Spero Therapeutics IncSPROreceived minutes from a recent Type A meeting with the FDA, discussing steps required to resubmit the marketing application for tebipenem HBr for complicated urinary tract infection (cUTI).
During the Type A meeting, the FDA indicated that positive results from an additional Phase 3 trial supported by confirmatory nonclinical efficacy evidence could be sufficient to support the approval of tebipenem HBr for cUTI, including pyelonephritis for a limited use indication.
Spero and the FDA also aligned the key components of the proposed pivotal Phase 3 trial design, which may be the subject of a Special Protocol Assessment request, to be confirmed once the clinical protocol is finalized.
Spero received a Complete Response Letter from the FDA in June 2022, citing data from Spero’s initial Phase 3 cUTI clinical trial, ADAPT-PO, that were insufficient to support approval.
